Potassium-increasing regimens in patients at high risk of ventricular arrhythmias: a prespecified observational analysis of the randomized POTCAST trial
Europace · 2026
DOI: 10.1093/europace/euag272 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Europace, 2026. Verfasst von Elisabeth Margrethe Danielsen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Heart Centre, Copenhagen University Hospital-Rigshospitalet, Blegdamsvej 9, Copenhagen Ø 2100, Denmark. Hauptthemen laut MEDLINE: Arrhythmias, Cardiac, Defibrillators, Implantable, Dietary Supplements, Hyperkalemia. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Independent Research Fund Denmark, Novo Nordisk Foundation, Danish Heart Foundation.
Abstract (Originalsprache)
Aims
The POTCAST trial (n = 1200) showed that targeting high-normal plasma potassium levels reduced ventricular arrhythmias in patients with implantable cardioverter-defibrillators (ICDs). We compared changes in plasma potassium and described outcomes across the three regimens used to increase plasma potassium.
Methods
We studied 600 control participants and 572 intervention participants who completed potassium up-titration in POTCAST. Participants in the intervention arm were categorized according to treatment after plasma-potassium up-titration into (i) mineralocorticoid-receptor antagonists (MRAs) monotherapy, (ii) potassium-supplement monotherapy, or (iii) combination therapy with both. The primary endpoint was a composite of sustained ventricular arrhythmia, appropriate ICD therapy, hospitalization for arrhythmia or heart failure, or all-cause mortality. Safety outcomes included death and electrolyte/renal disturbances.
Results
After 6 months, plasma potassium increased from 4.12 to 4.27 mmol/L (P = 0.004) with MRA, from 3.99 to 4.24 mmol/L (P < 0.001) with potassium supplements, and from 3.98 to 4.34 mmol/L (P < 0.001) with combination therapy. The primary endpoint occurred in 29% (n = 175) of controls, 22% (n = 16) in the MRA group, 21% (n = 31) in the potassium supplements group, and 22% (n = 72) in the combination therapy group (P = 0.8 between regimens). Hypokalemia occurred in 13% of controls and in 3, 9, and 5% of participants receiving MRA, potassium supplements, and combination therapy, respectively. Hyperkalemia occurred in 0.2% of controls and in 0, 3, and 4% of participants receiving MRA, potassium supplements, and combination therapy (P > 0.1 between regimens).
Conclusion
Treatment with MRA, potassium supplements, or both increased potassium levels. All regimens were associated with numerically lower endpoint rates than controls. We detected no statistically significant differences in endpoints or safety between regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The Heart Centre, Copenhagen University Hospital-Rigshospitalet, Blegdamsvej 9, Copenhagen Ø 2100, Denmark.
- Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Herlev Ringvej 75, Herlev 2730, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Blegdamsvej 3B, Copenhagen N 2200, Denmark.
- Department of Cardiology, Zealand University Hospital-Roskilde, Sygehusvej 10, Roskilde 4000, Denmark.
ORCID-Profile: Elisabeth Margrethe Danielsen, Emil Anton Frandsen, Ulrik Christian Gudbrand Winsløw, Chaoqun Zheng, Tharsika Sakthivel, Kasper Karmark Iversen, Niels Risum, Christian Jøns
Förderung
- Independent Research Fund Denmark
- Novo Nordisk Foundation
- Danish Heart Foundation
Zitieren
APA
Danielsen, E. M., Frandsen, E. A., Winsløw, U. C. G., Zheng, C., Sakthivel, T., Iversen, K. K., Skovmand Bosselmann, H., Risum, N., Bundgaard, H., & Jøns, C. (2026). Potassium-increasing regimens in patients at high risk of ventricular arrhythmias: a prespecified observational analysis of the randomized POTCAST trial. Europace. https://doi.org/10.1093/europace/euag272
Vancouver
Danielsen EM, Frandsen EA, Winsløw UCG, Zheng C, Sakthivel T, Iversen KK, et al. Potassium-increasing regimens in patients at high risk of ventricular arrhythmias: a prespecified observational analysis of the randomized POTCAST trial. Europace. 2026. doi:10.1093/europace/euag272
BibTeX
@article{Danielsen2026,
author = {Danielsen, Elisabeth Margrethe and Frandsen, Emil Anton and Winsløw, Ulrik Christian Gudbrand and Zheng, Chaoqun and Sakthivel, Tharsika and Iversen, Kasper Karmark and Skovmand Bosselmann, Helle and Risum, Niels and Bundgaard, Henning and Jøns, Christian},
title = {Potassium-increasing regimens in patients at high risk of ventricular arrhythmias: a prespecified observational analysis of the randomized POTCAST trial},
journal = {Europace},
year = {2026},
doi = {10.1093/europace/euag272}
}
EUVIMED